The impact of stroke and bleeding on mortality and quality of life during the first year after TAVI: A POPular TAVI subanalysis.
aortic stenosis
bleeding
mortality
quality of life
stroke
transcatheter aortic valve implantation
Journal
Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions
ISSN: 1522-726X
Titre abrégé: Catheter Cardiovasc Interv
Pays: United States
ID NLM: 100884139
Informations de publication
Date de publication:
11 Sep 2024
11 Sep 2024
Historique:
revised:
27
07
2024
received:
30
04
2024
accepted:
25
08
2024
medline:
11
9
2024
pubmed:
11
9
2024
entrez:
11
9
2024
Statut:
aheadofprint
Résumé
Bleeding and stroke are frequent complications after transcatheter aortic valve implantation (TAVI). The mortality risk associated with these events has been reported before, but data regarding their impact on health-related quality of life (QoL) is limited. To evaluate the impact of bleeding and stroke occurring within 30 days after TAVI, on mortality and QoL during the first year after TAVI. POPular TAVI was a randomized clinical trial that evaluated the addition of clopidogrel to aspirin or oral anticoagulation in patients undergoing TAVI. Besides clinical outcomes, QoL was assessed using the Short Form-12 and EuroQoL Five Dimensions questionnaires before, and at 3, 6, and 12 months after TAVI. Major or life-threatening bleeding occurred in 81 patients (8.3%) and was associated with an increased risk of death (hazard ratio [HR] 1.95 [95% confidence interval (CI) 1.00-3.79]); minor bleeding occurred in 104 patients (10.6%) and was not associated with mortality (HR 0.75 [95% CI 0.30-1.89]). Stroke occurred in 35 patients (3.6%) and was associated with an increased risk of death (HR 2.90 [95% CI 1.23-6.83]). Mean mental component summary (MCS-12) scores over time were lower in patients with major or life-threatening bleeding (p = 0.01), and similar in patients with minor bleeding, compared to patients without bleeding; mean physical component summary (PCS-12) scores, EQ-5D index, and visual analog scale (VAS) were similar between those patients. Mean MCS-12 scores were lower in patients with stroke (p = 0.01), mean PCS-12, EQ-5D index, and VAS were similar compared to patients without stroke. Major or life-threatening bleeding and stroke were associated with an increased risk of death and decreased mental QoL in the first year after TAVI.
Sections du résumé
BACKGROUND
BACKGROUND
Bleeding and stroke are frequent complications after transcatheter aortic valve implantation (TAVI). The mortality risk associated with these events has been reported before, but data regarding their impact on health-related quality of life (QoL) is limited.
AIM
OBJECTIVE
To evaluate the impact of bleeding and stroke occurring within 30 days after TAVI, on mortality and QoL during the first year after TAVI.
METHODS
METHODS
POPular TAVI was a randomized clinical trial that evaluated the addition of clopidogrel to aspirin or oral anticoagulation in patients undergoing TAVI. Besides clinical outcomes, QoL was assessed using the Short Form-12 and EuroQoL Five Dimensions questionnaires before, and at 3, 6, and 12 months after TAVI.
RESULTS
RESULTS
Major or life-threatening bleeding occurred in 81 patients (8.3%) and was associated with an increased risk of death (hazard ratio [HR] 1.95 [95% confidence interval (CI) 1.00-3.79]); minor bleeding occurred in 104 patients (10.6%) and was not associated with mortality (HR 0.75 [95% CI 0.30-1.89]). Stroke occurred in 35 patients (3.6%) and was associated with an increased risk of death (HR 2.90 [95% CI 1.23-6.83]). Mean mental component summary (MCS-12) scores over time were lower in patients with major or life-threatening bleeding (p = 0.01), and similar in patients with minor bleeding, compared to patients without bleeding; mean physical component summary (PCS-12) scores, EQ-5D index, and visual analog scale (VAS) were similar between those patients. Mean MCS-12 scores were lower in patients with stroke (p = 0.01), mean PCS-12, EQ-5D index, and VAS were similar compared to patients without stroke.
CONCLUSION
CONCLUSIONS
Major or life-threatening bleeding and stroke were associated with an increased risk of death and decreased mental QoL in the first year after TAVI.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024 Wiley Periodicals LLC.
Références
Corrigendum to: 2021 ESC/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio‐Thoracic Surgery (EACTS). Eur Heart J. 2022;43(21):2022. doi:10.1093/eurheartj/ehac051
Otto CM, Nishimura RA, Bonow RO, et al. 2020 ACC/AHA Guideline for the Management of Patients With Valvular Heart Disease: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2021;143(5):35. doi:10.1161/CIR.0000000000000932
Iung B, Cachier A, Baron G, et al. Decision‐making in elderly patients with severe aortic stenosis: why are so many denied surgery? Eur Heart J. 2005;26(24):2714‐2720. doi:10.1093/eurheartj/ehi471
Grube E, Schuler G, Buellesfeld L, et al. Percutaneous aortic valve replacement for severe aortic stenosis in high‐risk patients using the second‐ and current third‐generation self‐expanding core valve prosthesis. J Am Coll Cardiol. 2007;50(1):69‐76. doi:10.1016/j.jacc.2007.04.047
van Ginkel DJ, Bor WL, Veenstra L, van 't Hof AWJ, Fabris E. Evolving concepts in the management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation. Eur J Intern Med. 2022;101:14‐20. doi:10.1016/j.ejim.2022.05.002
Patel PA, Patel S, Feinman JW, et al. Stroke after transcatheter aortic valve replacement: incidence, definitions, etiologies and management options. J Cardiothorac Vasc Anesth. 2018;32(2):968‐981. doi:10.1053/j.jvca.2017.08.034
Pilgrim T, Stortecky S, Luterbacher F, Windecker S, Wenaweser P. Transcatheter aortic valve implantation and bleeding: incidence, predictors and prognosis. J Thromb Thrombolysis. 2013;35(4):456‐462. doi:10.1007/s11239-012-0842-3
Muralidharan A, Thiagarajan K, Van Ham R, et al. Meta‐Analysis of perioperative stroke and mortality in transcatheter aortic valve implantation. Am J Cardiol. 2016;118(7):1031‐1045. doi:10.1016/j.amjcard.2016.07.011
Elmalem S, Dumonteil N, Marcheix B, et al. Health‐Related quality of life after transcatheter aortic valve implantation in elderly patients with severe aortic stenosis. J Am Med Dir Assoc. 2014;15(3):201‐206. doi:10.1016/j.jamda.2013.11.010
Georgiadou P, Kontodima P, Sbarouni E, et al. Long‐term quality of life improvement after transcatheter aortic valve implantation. Am Heart J. 2011;162(2):232‐237. doi:10.1016/j.ahj.2011.06.004
Arnold SV, Zhang Y, Baron SJ, et al. Impact of Short‐Term complications on mortality and quality of life after transcatheter aortic valve replacement. JACC: Cardiovascular Interventions. 2019;12(4):362‐369. doi:10.1016/j.jcin.2018.11.008
Van Mieghem NM, Unverdorben M, Hengstenberg C, et al. Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR. N Engl J Med. 2021;385(23):2150‐2160. doi:10.1056/NEJMoa2111016
Collet JP, Van Belle E, Thiele H, et al. Apixaban vs. standard of care after transcatheter aortic valve implantation: the ATLANTIS trial. Eur Heart J. 2022;43(29):2783‐2797. doi:10.1093/eurheartj/ehac242
Nijenhuis VJ, Bennaghmouch N, Hassell M, et al. Rationale and design of POPular‐TAVI: antiplatelet therapy for patients undergoing transcatheter aortic valve implantation. Am Heart J. 2016;173:77‐85. doi:10.1016/j.ahj.2015.11.008
Nijenhuis VJ, Brouwer J, Delewi R, et al. Anticoagulation with or without clopidogrel after transcatheter aortic‐valve implantation. N Engl J Med. 2020;382(18):1696‐1707. doi:10.1056/NEJMoa1915152
Brouwer J, Nijenhuis VJ, Delewi R, et al. Aspirin with or without clopidogrel after transcatheter aortic‐valve implantation. N Engl J Med. 2020;383(15):1447‐1457. doi:10.1056/NEJMoa2017815
Kappetein AP, Head SJ, Genereux P, et al. Updated standardized endpoint definitions for transcatheter aortic valve implantation: the valve academic research consortium‐2 consensus document (VARC‐2). Eur J Cardiothorac Surg. 2012;42(5):S45‐S60. doi:10.1093/ejcts/ezs533
Ware JE, Kosinski M, Keller SD. SF‐12: How to Score the SF‐12 Physical and Mental Health Summary Scales. 2nd Edition. The Health Institute; 1995.
Farivar SS, Cunningham WE, Hays RD. Correlated physical and mental health summary scores for the SF‐36 and SF‐12 Health Survey, V.1. Health Qual Life Outcomes. 2007;5(1):54. doi:10.1186/1477-7525-5-54
M. Versteegh M, M. Vermeulen K, M. A. A. Evers S, de Wit GA, Prenger R, A. Stolk E. Dutch tariff for the five‐level version of EQ‐5D. Value Health. 2016;19(4):343‐352. doi:10.1016/j.jval.2016.01.003
Van Reenen M, Janssen B, Stolk E, et al. CHANGES INCLUDED in This Update of the EQ‐5D‐5L User Guide Table of Contents.
Wang J, Yu W, Jin Q, et al. Risk factors for post‐TAVI bleeding according to the VARC‐2 bleeding definition and effect of the bleeding on short‐term mortality: a meta‐analysis. Can J Cardiol. 2017;33(4):525‐534. doi:10.1016/j.cjca.2016.12.001
Kochman J, Rymuza B, Huczek Z, et al. Incidence, predictors and impact of severe periprocedural bleeding according to VARC‐2 criteria on 1‐year clinical outcomes in patients after transcatheter aortic valve implantation. Int Heart J. 2016;57(1):35‐40. doi:10.1536/ihj.15-195
Konigstein M, Ben‐Assa E, Banai S, et al. Periprocedural bleeding, acute kidney injury, and long‐term mortality after transcatheter aortic valve implantation. Can J Cardiol. 2015;31(1):56‐62. doi:10.1016/j.cjca.2014.11.006
van Ginkel DJ, Brouwer J, van Hemert ND, et al. Major threats to early safety after transcatheter aortic valve implantation in a contemporary cohort of real‐world patients. Neth Heart J. 2021;29(12):632‐642. doi:10.1007/s12471-021-01638-8
Vlastra W, Jimenez‐Quevedo P, Tchétché D, et al. Predictors, incidence, and outcomes of patients undergoing transfemoral transcatheter aortic valve implantation complicated by stroke. Circ Cardiovasc Interv. 2019;12(3):e007546. doi:10.1161/CIRCINTERVENTIONS.118.007546
Capodanno D, Collet JP, Dangas G, et al. Antithrombotic therapy after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2021;14(15):1688‐1703. doi:10.1016/j.jcin.2021.06.020
Reynolds MR, Magnuson EA, Lei Y, et al. Health‐Related quality of life after transcatheter aortic valve replacement in inoperable patients with severe aortic stenosis. Circulation. 2011;124(18):1964‐1972. doi:10.1161/CIRCULATIONAHA.111.040022
Arnold SV, Spertus JA, Vemulapalli S, et al. Quality‐of‐life outcomes after transcatheter aortic valve replacement in an unselected population. JAMA Cardiol. 2017;2(4):409. doi:10.1001/jamacardio.2016.5302
Georgiadou P, Kontodima P, Sbarouni E, et al. Long‐term quality of life improvement after transcatheter aortic valve implantation. Am Heart J. 2011;162(2):232‐237. doi:10.1016/j.ahj.2011.06.004
Elmalem S, Dumonteil N, Marcheix B, et al. Health‐related quality of life after transcatheter aortic valve implantation in elderly patients with severe aortic stenosis. J Am Med Dir Assoc. 2014;15(3):201‐206. doi:10.1016/j.jamda.2013.11.010
Arnold SV, Zhang Y, Baron SJ, et al. Impact of short‐term complications on mortality and quality of life after transcatheter aortic valve replacement. JACC Cardiovasc Interv. 2019;12(4):362‐369. doi:10.1016/j.jcin.2018.11.008
van Ginkel DJ, Bor WL, Dubois CLF, et al. Periprocedural continuation versus interruption of oral anticoagulant drugs during transcatheter aortic valve implantation: rationale and design of the POPular PAUSE TAVI trial. EuroIntervention. 2023;19:766‐771. doi:10.4244/EIJ-D-23-00206
Arnold SV, Spertus JA, Vemulapalli S, et al. Association of patient‐reported health status with long‐term mortality after transcatheter aortic valve replacement. Circ Cardiovasc Interv. 2015;8(12):e002875. doi:10.1161/CIRCINTERVENTIONS.115.002875
Arnold SV, Spertus JA, Lei Y, et al. Use of the Kansas City Cardiomyopathy Questionnaire for monitoring health status in patients with aortic stenosis. Circ Heart Fail. 2013;6(1):61‐67. doi:10.1161/CIRCHEARTFAILURE.112.970053
Styra R, Dimas M, Svitak K, et al. Toronto aortic stenosis quality of life questionnaire (TASQ): validation in TAVI patients. BMC Cardiovasc Disord. 2020;20(1):209. doi:10.1186/s12872-020-01477-2
Frank D, Kennon S, Bonaros N, et al. Quality of life measures in aortic stenosis research: a narrative review. Cardiology. 2023;148:556‐570. doi:10.1159/000531465